Category: Zacks Small Cap Research
By Lisa Thompson NASDAQ:RCRT READ THE FULL RCRT RESEARCH REPORT In Q1 Recuiter.com (NASDAQ:RCRT) continued its march to higher revenues and cash flow breakeven aided by its more than doubling of revenues and a gross margin improvement of 10.5 percent ...
By Ann Heffron, CFA, CPA OTC:CPKF READ THE FULL CPKF RESEARCH REPORT CPKF’s (OTC:CPKF) first quarter net earnings decreased $1.0 million, or 19%, year over year to $4.3 million, while 2022’s first quarter diluted EPS fell by $0.18, or 18%, to $0.90 f ...
By M. Marin NYSE:CXW READ THE FULL CXW RESEARCH REPORT Credit facilities underscore CXW stable revenue, strengthening balance sheet… CoreCivic (NYSE:CXW) announced new credit facilities this week, comprised of a $100 million term loan and $250 millio ...
By Brad Sorensen, CFA NASDAQ:ENSC READ THE FULL ENSC RESEARCH REPORT Ensysce Biosciences (NASDAQ:ENSC) is a California-based clinical-stage pharmaceutical company behind programs that could provide hope for the millions impacted by opioid addiction a ...
By John Vandermosten, CFA NYSE:PLX READ THE FULL PLX RESEARCH REPORT Protalix Biotherapeutics, Inc. (NYSE:PLX) announced its 1Q:22 financial and operational results in a May 16, 2022 press release and filing of Form 10-Q. The materials were followed ...
By John Vandermosten, CFA NASDAQ:GBS READ THE FULL GBS RESEARCH REPORT GBS, Inc. (NASDAQ:GBS) announced third quarter fiscal year 2022 financial and operational results for the period ending March 31, 2022 in a May 10th press release and subsequently ...
By David Bautz, PhD NASDAQ:ARWR READ THE FULL ARWR RESEARCH REPORT Business Update Cardiometabolic Programs Progressing Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) has two late-stage cardiometabolic programs, ARO-APOC3 and ARO-ANG3. ARO-APOC3 is ta ...
By Brad Sorensen, CFA OTC:EMMA READ THE FULL EMMA RESEARCH REPORT Emmaus Life Sciences (OTC:EMMA) announced 1Q 2022 earnings of -$0.03 per share while revenues in the first quarter declined to $3.2 million from $5.3 million the year before. Managemen ...
By Lisa Thompson NASDAQ:POET READ THE FULL POET RESEARCH REPORT Since POET (NASDAQ:POET) reported Q4, not much has changed on the news front from the Q1 report. However, at its presentation at the Sidoti conference, the company gave some insight into ...
By Lisa Thompson NASDAQ:TSEM READ THE FULL TSEM RESEARCH REPORT Tower Semiconductor (NASDAQ:TSEM) reported revenues and earnings above expectations in Q1 2022 of $421 million versus $347 million in Q1 2021. The company is no longer providing guidance ...